FDA Panel Gives Nod to New Blincyto Use in ALL

Share this post

Blinatumomab would become the first treatment for which minimal residual disease positivity would be a selection criterion and MRD negativity an endpoint for acute lymphoblastic leukemia.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply